Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulse: Reduced Dose Maintenance Pembrolizumab in Non-Squamous NSCLC
NCT05692999Phase 3Recruiting
- Sponsor
- Gustave Roussy
- Start
- Mar 2023
- Primary completion
- Jan 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 3 trial of pembrolizumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Gustave Roussy. Started Mar 2023; status: recruiting.
02
Drugs
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT05692999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05692999.